中关村(000931.SZ)下属公司西格列汀二甲双胍片(II)上市许可申请获得受理

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1: Company Developments - Duoduo Pharmaceutical's Sitagliptin Metformin Tablets (II) contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - The product was initiated for development in 2023 and is indicated for use in combination with diet and exercise to treat type 2 diabetes patients who have inadequate blood sugar control with Metformin monotherapy or are currently receiving both treatments [1]